Bottom line
IBB vs FBIOX: the short answer
IBB (iShares Biotechnology ETF) and FBIOX (Biotechnology Portfolio) are quite different portfolios: only about 34% of their top holdings (by weight) are shared.
IBB is cheaper at 0.44% vs 0.62% — a difference of $18 a year per $10,000 invested.
Over five years, FBIOX returned +3.5% a year vs +2.5% for IBB (reporting dates differ).
Updated Nov 19, 2026
IBB vs FBIOX side by side
| IBB | FBIOX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Fidelity |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 0.62% |
| Annual cost per $10k | $44 | $62 |
| 10-yr cost on $10k (prospectus) | $555 | $774 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +28.0% | +36.4% |
| 5-yr return (annualized) | +2.5% | +3.5% |
| 10-yr return (annualized) | +4.4% | +6.9% |
| Best quarter | +26.8% | +33.6% |
| Worst quarter | −22.9% | −28.4% |
| Net assets (fund) | $5.9B | $5.3B |
| Number of holdings | 254 | 215 |
| Portfolio turnover | 27% | 45% |
| Returns as of | Dec 31, 2025 | Apr 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | FBIOX | Difference |
|---|---|---|---|
| 2025 | +28.0% | +36.4% | −8.4% |
| 2024 | −2.4% | +7.3% | −9.7% |
| 2023 | +3.6% | +10.1% | −6.5% |
| 2022 | −13.6% | −15.9% | +2.3% |
| 2021 | +1.0% | −12.4% | +13.4% |
| 2020 | +25.9% | +38.3% | −12.4% |
| 2019 | +24.8% | +36.0% | −11.2% |
| 2018 | −9.1% | −10.7% | +1.6% |
| 2017 | +21.2% | +27.9% | −6.7% |
| 2016 | −21.5% | −23.7% | +2.2% |
Source: Fund prospectus bar charts
Holdings overlap
9 of IBB's top 25 holdings also appear in FBIOX's top 25.
| Holding | IBB | FBIOX |
|---|---|---|
| Gilead Sciences, Inc. | 7.52% | 4.82% |
| Amgen, Inc. | 7.50% | 6.53% |
| Alnylam Pharmaceuticals, Inc. | 5.68% | 2.93% |
| Argenx SE | 3.15% | 2.25% |
| Insmed, Inc. | 2.95% | 2.25% |
| Natera, Inc. | 2.11% | 1.41% |
| Biogen, Inc. | 2.03% | 1.26% |
| Madrigal Pharmaceuticals, Inc. | 0.92% | 0.93% |
| Moderna, Inc. | 0.88% | 1.28% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FBIOX top 10
- Krystal Biotech Inc — 10.58%
- Abbvie Inc — 9.22%
- Amgen Inc — 6.53%
- Gilead Sciences Inc — 4.82%
- Fidelity Revere Street Trust — 3.35%
- Alnylam Pharmaceuticals Inc — 2.93%
- Praxis Precision Medicines Inc. — 2.47%
- Insmed Inc — 2.25%
- Argenx Se — 2.25%
- Ascendis Pharma A/s — 2.04%
FAQ
What is the difference between IBB and FBIOX?
Which is cheaper, IBB or FBIOX?
Should I own both IBB and FBIOX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.